Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAiL: Bevacizumab + chemotherapy in advanced NSCLC
NCT00451906Phase 4Completed
- Sponsor
- Roche
- Start
- Aug 2006
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 40
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events of Special Interest up to 3 years and Number of Participants With Serious Adverse Events Related to Bevacizumab up to 3 years. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00451906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451906.